<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>RDM OCDEM</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/3918F1AA-7A9E-41F9-8D0E-FF7BB8441905"><gtr:id>3918F1AA-7A9E-41F9-8D0E-FF7BB8441905</gtr:id><gtr:firstName>Gerard</gtr:firstName><gtr:otherNames>Vincent</gtr:otherNames><gtr:surname>Walls</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0501780"><gtr:id>135A1EDC-54EC-47F0-BFBF-6A3AF4DC961D</gtr:id><gtr:title>Gene therapy for multiple endocrine neoplasia type 1 (MEN1)</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0501780</gtr:grantReference><gtr:abstractText>The basic concept of gene therapy is simple, and this is to introduce a normal gene into a cell that has a defective gene, and the product of the normal gene should cure or slow down the progression of the disease. I propose to use this approach to treat endocrine tumours in the disorder of Multiple Endocrine Neoplasia type 1 (MEN1) that results from a single gene defect. Medical and surgical treatments are frequently unsuccessful in this disorder which is inherited and starts at an early age. I propose to use gene therapy to treat these tumours. Professor Thakker?s group, at The University of Oxford, have identified the MEN1 gene and established a mouse model that develops the same tumours that are found in MEN1 patients. I now propose to attach the MEN1 gene to a modified virus (i.e. one with its harmful genes removed), to develop a gene therapy for MEN1 patients. I will test the effectiveness and safety of this MEN1 replacement virus in tumour cells and then use it to treat tumours in the mouse model. The results, if successful, will provide an important new treatment for MEN1 patients.</gtr:abstractText><gtr:technicalSummary>Aims / objective:

1. MEN1 tumours, and therapy to suppress tumourigenicity
2. To gain training in molecular and tumour biology

Background / design:

Multiple Endocrine Neoplasia type 1 (MEN1) is an autosomal dominant disorder characterised by the combined occurrence of tumours of the parathyroids, pancreatic islets and anterior pituitary. Some patients may also develop adrenal and carcinoid tumours. Treatment for MEN1, which is caused by a single gene located on chromosome 11q13, is frequently unsuccessful. I therefore propose to develop MEN1 gene replacement therapy. I now propose to: 1) construct a retroviral-based amphotropic MEN1 gene therapy vector; 2) assess the effectiveness and safety of this vector in vitro using tumour cell cultures and 3) assess the effectiveness and safety of this vector in vivo using tumours that develop in MEN1 +/- knockout mice.

Scientific and medical opportunities of the study:

These studies will assess the feasibility of gene therapy for MEN1 using a retroviral construct and will also increase our understanding of tumourigenesis and cell proliferation.

Methodology:

Training in methods of molecular and tumour biology. This will include generating a viral agent therapy construct; DNA sequence analysis and the use of PCR; cell culture and immunohistochemistry techniques; Southern, Northern and Western blot analyses; appropriate use of mouse models and the use of bioinformatic computer programs for sequence analysis, protein and EST database searches.</gtr:technicalSummary><gtr:fund><gtr:end>2009-10-03</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-10-04</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>204791</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novartis</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Somatostatin analogue trial</gtr:description><gtr:id>20DD04EF-F57F-4756-942F-D340F81279F0</gtr:id><gtr:impact>Interim report provided to funder of preliminary finding in October 2013 resulting in further funding transferred.</gtr:impact><gtr:outcomeId>5277c52d9bd95-1</gtr:outcomeId><gtr:partnerContribution>Provision of materials and funding</gtr:partnerContribution><gtr:piContribution>Investigation of efficacy of somatostatin analogue treatment on neuroendocrine tumor progression and survival in a pre-clinical model</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>OCDEM Masterclass</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6D8FFD9A-F312-40A8-8FC5-00B1708C49E7</gtr:id><gtr:impact>Masterclass in MEN1 for latin american endocrinologists, at the 3rd Latin American Knowledge Network Conference, Harris Manchester College, Oxford , UK.

Bilateral discussions over endocrinology and fostering of network reltionships to enhance future clinical studies.</gtr:impact><gtr:outcomeId>52782756a1c6c</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>WNT BES 2010</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B9D8044D-B742-418C-9379-BC6133E39D5F</gtr:id><gtr:impact>British Endocrine Society 2010, Manchester, UK, 15-18 March 2010.
'Wnt/beta-catenin signalling is down-regulated in pituitary tumours from a Multiple Endocrine Neoplasia Type 1 (MEN1) mouse model.' GV Walls, PJ Newey, MA Nesbit, J Jeyabalan, H Schulz, N Huebner &amp;amp; RV Thakker. Endocrine Abstracts 2010; 21: OC2.2.

Delegate discussions and networking opportunities</gtr:impact><gtr:outcomeId>J55nD22TvZA</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:url>http://www.endocrine-abstracts.org/ea/0021/ea0021oc2.2.htm</gtr:url><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Pituitary apoptosis BES 2010</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>930A59CC-937F-4145-8925-4CC0CA153D2A</gtr:id><gtr:impact>Society for Endocrinology British Endocrine Society 2010, Manchester, 15-18 March 2010.
'Pituitary tumours of mice deleted for a multiple endocrine neoplasia type 1 allele have alterations in apoptotic pathway components.' Gerard Walls, Paul Newey, Jeshmi Jeyabalan, A Michael Nesbit, Herbert Schulz, Norbert Huebner &amp;amp; Rajesh Thakker. Endocrine Abstracts 2010; 21: P304.

Delegate discussion and networking with peers</gtr:impact><gtr:outcomeId>52781e43cc038</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.endocrinology.org/meetings/2010/sfebes2010/</gtr:url><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BES 2013 Young Endocrinologists' Prize Lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D840DA98-8A36-4F80-BE95-0F3C3406F43B</gtr:id><gtr:impact>Society for Endocrinology Young Endocrinologist' Clinical Prize lecture at the British Endocrine Society Meeting 18th - 21st March 2013

Generated interest in my work leading to a journal article relaying the details of my work and this activity.</gtr:impact><gtr:outcomeId>52782757148e3</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.endocrinology.org/meetings/2013/sfebes2013/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Journal Article Endocrinologist 2013</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CF5FD861-CA79-4EF0-9DC9-32DA74A9079A</gtr:id><gtr:impact>Report on Society for Endocrinology Young Endorinologists' Clinical Prize Lecture

Invited by media to discuss my presentation on gene therapy in MEN1 tumours in order to disseminate the research note widely, and inform about the BES 2013 meeting.</gtr:impact><gtr:outcomeId>h41mQcTmXCN</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:url>http://endocrinology.org/endocrinologist/issue.aspx?issue=109</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Proliferation in MEN1 tumours ENDO 2010</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E0218BEF-5189-4287-A8FE-0E8804A7FBB9</gtr:id><gtr:impact>Discussion on assessing proliferation in vivo with delegates.
The Endocrine Society's 92nd Meeting, San Diego, USA June 2010.

Discussion on assessing proliferation in vivo with delegates and networking witrh peers.</gtr:impact><gtr:outcomeId>52781e4433bf5</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.endojournals.org/site/abstracts/abstracts.xhtml</gtr:url><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Parathyroid BES 2013</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9C9CDFC3-CD3A-481E-BAF3-E7164BD22C0F</gtr:id><gtr:impact>British Endocrine Society Annual Meeting 2013, Harrogate, UK.
'Parathyroid gland studies in mouse models for endocrine tumours defines anatomical locations and ultrastructural differences between normal and tumour cells.'
Gerard Walls, Anne Clark &amp;amp; Rajesh Thakker.


Potential research collaboration and contact made following presentaion.</gtr:impact><gtr:outcomeId>52782757bef11</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.endocrine-abstracts.org/ea/0031/ea0031p152.htm</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Electron microscopy of pancreatic beta cell neuroendocrine tumours in Multiple Endocrine Neoplasia type 1</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>166BA396-B56F-4CCC-9B39-F024B6FD1A35</gtr:id><gtr:impact>Presentation at 11th Annual European Neuroendocrine Tumour Society (ENETS) Conference, Barcelona, Spain. Interest, questions and networking with colleagues from across Europe and the UK.

Invitation to prepare a review on MEN syndromes</gtr:impact><gtr:outcomeId>545a9dc4aa7740.17481739</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UKINETS 2012</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>24CA5C19-E353-4555-A357-618EC93FFDAE</gtr:id><gtr:impact>UKI NETS 10th National Conference, 4 December 2012, Royal Society of Medicine, London. 
'Mathematical modelling of neuroendocrine tumour NET) growth in Multiple Endocrine Neoplasia type 1 (MEN1) knockout mice demonstrates second-order kinetics.' 
Walls GV. Presented with the award for the best scientific oral communication at the meeting. Considerable interest amongst delegates.

Prize money contribution for further research in this area.</gtr:impact><gtr:outcomeId>5278275766d0e</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.ukinets.org/events/2012/</gtr:url><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>American Endocrine Society 2010 NET Model</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A48D05F4-23B8-4DAD-B6E7-D1BAC85B0FB4</gtr:id><gtr:impact>The Endocrine Society's 92nd Meeting, 2010, San Diego, USA.
'Proliferation of Pancreatic Islet and Anterior Pituitary
Neuroendocrine Tumours (NETs) Developing in a Mouse
Model of Multiple Endocrine Neoplasia Type 1 (MEN1) Is
Consistent with a Third Order Regression Mathematical
Model.
GV Walls, J Jeyabalan, AAC Reed, NR Hill, B Harding and RV Thakker.
Elsevier Junior research prize: poster presentations in San Diego. 7000 delegates

Conference report submitted for publication</gtr:impact><gtr:outcomeId>QumJ35uCpWb</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.endojournals.org/site/abstracts/abstracts.xhtml</gtr:url><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UKINETS 2011 Mitotane</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>89A1F277-DC3C-4D46-8D72-463AD1FFDCE2</gtr:id><gtr:impact>UKI NETS 9th National Conference, London, UK.
'Response of metastatic disease to Mitotane therapy in patients with adrenocortical cancer despite suboptimal monitored levels below 14mg/L.' Walls G, Weaver A, Sadler G, Mihai R.
National meetings ~500 attendees. Many questions and discussion formally and informally.

Invited to give plenary talk</gtr:impact><gtr:outcomeId>QrBucb9ih3d</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:url>http://www.ukinets.org/events/2011/index.aspx</gtr:url><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BES 2008 Insulinoma</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B0433300-1917-440A-9BC1-F9B78FF87546</gtr:id><gtr:impact>Society for Endocrinology BES 2008, Harrogate, UK, 7-10 April 2008.
'Assessment of in vivo proliferation rates in insulinomas of multiple endocrine neoplasia type 1 knockout mice: implications for evaluating effectiveness of future treatments.'
GV Walls, AAC Reed, B Harding, J Jeyabalan &amp;amp; RV Thakker.

Discussions with delegates and networking.</gtr:impact><gtr:outcomeId>NzVjv6sc4iN</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:url>http://www.endocrine-abstracts.org/ea/0015/ea0015p175.htm</gtr:url><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>TBF beta signalling in pituitary ENDO 2010</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>861A2561-604E-4ECB-B32F-D1249597A926</gtr:id><gtr:impact>The Endocrine Society's 92nd Meeting, San Diego, USA, June 2010, TGF beta signalling in anterior pituitary NETs in MEN1

Discussion of signalling pathways in pituitary tumours and networking with peers.</gtr:impact><gtr:outcomeId>52781e449f920</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.endojournals.org/site/abstracts/abstracts.xhtml</gtr:url><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cdc73 parathyroids BES 2009</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4210DC1E-70A3-4060-9552-A0D2B226444D</gtr:id><gtr:impact>British Endocrine Society 2009, Harrogate, UK. 
 'Mice deleted for the Hyperparathyroidism-Jaw Tumour (HPT-JT) syndrome allele have abnormal parathyroids with increased proliferation rates.' G Walls, M Bowl, J Jeyabalan, A Reed, B Harding, A Ali, K Bradley, P Wang, J Chen, B Williams, B Teh &amp;amp; R Thakker. Endocrine Abstracts 2009; 19: OC30.

Requests to collaborate on further studies.</gtr:impact><gtr:outcomeId>AbwLEsKd4jA</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:url>http://www.endocrine-abstracts.org/ea/0019/ea0019oc30.htm</gtr:url><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Journal article Seminars in Paediatric Surgery</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>51FD852E-8997-4F48-BDD5-216A0C50BF97</gtr:id><gtr:impact>Article on MEN syndromes. Many email enquiries and network connections made. Invitations to give presentations ant meetings.

Many email enquiries and network connections made. Invitations to give presentations ant meetings.</gtr:impact><gtr:outcomeId>545a8f242853f7.76690552</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Uterine BES 2013</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>15CA3520-0F8A-42F0-8D49-246E1B4B3F2C</gtr:id><gtr:impact>Society for Endocrinology BES 2013, Harrogate, UK, 18 - 21 March 2013.
'Uterine tumours with loss of progesterone receptor expression develop in mice deleted for a cell division cycle 73 allele.' GV Walls, S Manek &amp;amp; RV Thakker. Endocrine Abstracts 2013; 31: OC5.7

Delegate discussion and networking opportunities</gtr:impact><gtr:outcomeId>hF2JfTNEhxB</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:url>http://www.endocrine-abstracts.org/ea/0031/ea0031oc5.7.htm</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Biological models of MEN1</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7C15B9F8-6C31-4205-8817-48BE89012CB0</gtr:id><gtr:impact>Recognistion of progress in the field of Multiple Endocrine neoplasia type 1 and address on biological models of this condition. 18th National Symposium on Regulatory Peptides, Belfast, UK.

Contacts to irish endocrinologists established for potential clinical studies.</gtr:impact><gtr:outcomeId>52781e4503d49</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:url>http://www.regpep-society.com/18th-International-Symposium-in.html</gtr:url><gtr:year>2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR Clinical Lectureship</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:fundingRef>913</gtr:fundingRef><gtr:id>8CCBAF10-8092-471E-BBD6-2E66011C9E41</gtr:id><gtr:outcomeId>qNErx83VbUb0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Somatostatin analogue trial</gtr:description><gtr:end>2014-04-02</gtr:end><gtr:fundingOrg>Novartis</gtr:fundingOrg><gtr:id>2A47C75E-61E0-458E-8EF4-8D93A5582B54</gtr:id><gtr:outcomeId>5277c7d00a21f</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2012-05-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Mathematical model that describes the daily growth of neuroendocrine tumours in MEN1</gtr:description><gtr:grantRef>G0501780</gtr:grantRef><gtr:id>0F0EB19F-3841-4C1A-983D-18EB782FC97D</gtr:id><gtr:impact>Published mathematical equations and data for NET model for prediction of tumour outcomes.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>5277ee0757eb8</gtr:outcomeId><gtr:protection>Protection not required</gtr:protection><gtr:title>Tools: Mathematical model of NET growth</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Latin American Knowledge Network Masterclass</gtr:description><gtr:geographicReach>South America</gtr:geographicReach><gtr:id>58075B73-14F8-49CC-BE55-6C0AD5768FB8</gtr:id><gtr:impact>Update on clinical practice guidelines and basic research into Multiple Endocrine Neoplasia Type 1.
&amp;gt;30 Endocrinologists from Latin America as delegates in Oxford, who will disseminate the training in improving clinical service delivery in Latin America.</gtr:impact><gtr:outcomeId>52782058890b9</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Biological models of MEN1</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1E513414-A5BB-475F-B3D5-7309627E7AD0</gtr:id><gtr:outcomeId>52781e6aca2a6</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Endocrine Cancer Predisposition Syndromes: Hereditary Paraganglioma, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2, and Hereditary Thyroid Cancer</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>4623D785-1859-4F61-AFEF-8986E5AA7A45</gtr:id><gtr:impact>Change in guidelines for surveillance of MEN1 mutation carriers, indicating need for assessment at a younger age</gtr:impact><gtr:outcomeId>WUNGLfBZ1yM</gtr:outcomeId><gtr:type>Citation in clinical reviews</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Clinical Practice guidelines for Multiple Endocrine Neoplasia type 1 (MEN1)</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>Clinical Practice guidelines for Multiple Endocrine Neoplasia type 1 (MEN1)</gtr:guidelineTitle><gtr:id>1DE1B8AC-6436-4794-A897-E7C7FD0A2DF6</gtr:id><gtr:impact>New international guidelines for the assessment, surveillance and clinical management of patients and relatives of patients with multiple endocrine neoplasia type 1, including earlier detection of cancer.</gtr:impact><gtr:outcomeId>oPvsLCrmRoH</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>Adenovirus-mediated delivery of wild type Men1 gene to pituitary tumours that have lost both copies of the Men1 gene</gtr:description><gtr:id>3DCB0A8E-3AF8-4E51-8987-23E5A9FC2348</gtr:id><gtr:impact>Men1 gene replacement therapy reduces proliferation in MEN1-associated tumours: Walls et al Cancer Research 2012; 72:5060-8</gtr:impact><gtr:outcomeId>mkV5VBEWMK7</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>MEN1 gene therapy for pituitary tumours</gtr:title><gtr:type>Therapeutic Intervention - Cellular and gene therapies</gtr:type><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Oral administration of BrdU (1mg/ml) in drinking water to mice provides a robust way of assessing the low proliferation rates in endocrine glands and endocrine tumours</gtr:description><gtr:id>7E6C23FA-4BA1-4DE5-853F-F093E6B8785F</gtr:id><gtr:impact>Dissemination of results of administering BrdU for the assessment of low proliferation rates in vivo: Walls et al. Endocrinology 2010; 153</gtr:impact><gtr:outcomeId>fg1bMDEQQoU</gtr:outcomeId><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Closed</gtr:status><gtr:title>Long-term BrdU administration for assessing cellular proliferation rates</gtr:title><gtr:type>Support Tool - For Fundamental Research</gtr:type><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>Equations to model the growth of neuroendocrine tumours in vivo from BrdU uptake studies replacing the need for in vivo experiments with in silico assessments</gtr:description><gtr:id>4DF5EB42-82B7-45CB-900C-6BF507C8F1FD</gtr:id><gtr:impact>Model for neuroendocrine tumour growth allowing prediction of treatment effects</gtr:impact><gtr:outcomeId>545aa2b9abbf26.87528256</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Mathematical modelling of neuroendocrine tumour growth</gtr:title><gtr:type>Computer model/algorithm</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Electron micrographs of pancreatic tissue assessment for lipofusin content to model age of cells</gtr:description><gtr:id>7EC13051-CE29-404D-9C49-2DF35AC89DB6</gtr:id><gtr:impact>Publication of lifespan of human and mammalian islet cells using lipofusin as a marker of age.
Diabetologia 2010; 53:321-330</gtr:impact><gtr:outcomeId>5277ec8a44e59</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Beta cell lifespan model</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Microarray data on pituitary tumours in MEN1 model</gtr:description><gtr:id>AF3053D9-B721-42B8-90C6-1AD93CC93EEC</gtr:id><gtr:impact>International presentation of dysregulated signalling pathways in pituitary tumours: Endocrine Reviews 2010; 31:S134 and S289</gtr:impact><gtr:outcomeId>5277e9367a30c</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Wnt signalling database</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Men1+/- mice develop parathyroid, pituitary and pancreatic neuroendocrine tumours and represent the human syndrome of multiple endocrine neoplasia type 1 (MEN1)</gtr:description><gtr:id>C8D27FE1-0EAF-4550-851C-D13EE2C59057</gtr:id><gtr:impact>Proof of concept for gene replacement therapy in MEN1-associated tumours: Cancer Research 2012; 72:5060-68</gtr:impact><gtr:outcomeId>RYfbx9P1Bgi</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Conventional MEN1 knockout mice</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Using daily cellular proliferation and apoptotic data from administration of BrdU in vivo, a mathematical model of NET growth was developed</gtr:description><gtr:id>48AC5858-9917-4370-B9CE-882839128990</gtr:id><gtr:impact>Publication of the mathematical models in Walls et al Endocrinology 2012; 153:0</gtr:impact><gtr:outcomeId>ZKQicnxutjX</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Mathematical modelling of neuroendocrine tumor (NET) growth</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Characterised knockout mouse model of multiple endocrine neoplasia type 1</gtr:description><gtr:id>4BFD3A03-801A-41C0-ABA1-D3C50E75B6B8</gtr:id><gtr:impact>Refined time-span for tumour development and mortality of affected mice, leading to improved husbandry and surveillance protocols</gtr:impact><gtr:outcomeId>5277eca119f60</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Improved MEN1 model</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>BrdU is a thymidine analogue, specifically taken up during S-phase of the cell cycle and is used to specifically label proliferating cells. Long term administration in drinking water enables assessment of the low proliferation rates of endocrine tissues and endocrine tumours</gtr:description><gtr:id>C408ACB5-F774-4EB9-AD18-5F774EA37162</gtr:id><gtr:impact>Publication of proliferation rates in endocrine tumours of MEN1 knockout mice, and description of in vivo methods fro assessing proliferation: Walls et al Endocrinology 2012; 153:5167-79</gtr:impact><gtr:outcomeId>NCo1Pczitmi</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Assessment of in vivo cellular proliferation rates</gtr:title><gtr:type>Physiological assessment or outcome measure</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>81C90D22-6CC6-4D53-B817-D1B66F0E1B18</gtr:id><gtr:title>Pasireotide Therapy of Multiple Endocrine Neoplasia Type 1-Associated Neuroendocrine Tumors in Female Mice Deleted for an Men1 Allele Improves Survival and Reduces Tumor Progression.</gtr:title><gtr:parentPublicationTitle>Endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08a67913704857049cd961e429f8dd62"><gtr:id>08a67913704857049cd961e429f8dd62</gtr:id><gtr:otherNames>Walls GV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0013-7227</gtr:issn><gtr:outcomeId>56efd1f4e314d9.64310010</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A2579181-456A-4581-B813-F6BDEBB99E2D</gtr:id><gtr:title>Asymptomatic children with multiple endocrine neoplasia type 1 mutations may harbor nonfunctioning pancreatic neuroendocrine tumors.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4012bab03e044a389467d6bd29325d39"><gtr:id>4012bab03e044a389467d6bd29325d39</gtr:id><gtr:otherNames>Newey PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>A9323022FB3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CBF27238-A2AC-4706-83A9-7F93DAEBD19C</gtr:id><gtr:title>Genetic background influences embryonic lethality and the occurrence of neural tube defects in Men1 null mice: relevance to genetic modifiers.</gtr:title><gtr:parentPublicationTitle>The Journal of endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3718206226347df518c75fe2f24c131a"><gtr:id>3718206226347df518c75fe2f24c131a</gtr:id><gtr:otherNames>Lemos MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-0795</gtr:issn><gtr:outcomeId>7B0EF0828D5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE950623-1AEA-41B0-AD73-06C692072AED</gtr:id><gtr:title>Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1).</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b52b61d3e3709d22522d044d591de5c9"><gtr:id>b52b61d3e3709d22522d044d591de5c9</gtr:id><gtr:otherNames>Thakker RV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>pm_12939_29_22723327</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0BD5346B-C518-4D9D-BC8C-66DD7C167438</gtr:id><gtr:title>Multiple endocrine neoplasia type 1 knockout mice develop parathyroid, pancreatic, pituitary and adrenal tumours with hypercalcaemia, hypophosphataemia and hypercorticosteronaemia.</gtr:title><gtr:parentPublicationTitle>Endocrine-related cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/70b86cba6ffbb0385b12ed04c952995c"><gtr:id>70b86cba6ffbb0385b12ed04c952995c</gtr:id><gtr:otherNames>Harding B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1351-0088</gtr:issn><gtr:outcomeId>65BD5FAE91C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9626D459-487B-4423-9733-0CEC7881146F</gtr:id><gtr:title>Proliferation rates of multiple endocrine neoplasia type 1 (MEN1)-associated tumors.</gtr:title><gtr:parentPublicationTitle>Endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08a67913704857049cd961e429f8dd62"><gtr:id>08a67913704857049cd961e429f8dd62</gtr:id><gtr:otherNames>Walls GV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0013-7227</gtr:issn><gtr:outcomeId>pm_12939_29_23024266</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E2F0D374-2015-4065-B0E1-945D495C5EDF</gtr:id><gtr:title>Multiple endocrine neoplasia (MEN) syndromes.</gtr:title><gtr:parentPublicationTitle>Seminars in pediatric surgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08a67913704857049cd961e429f8dd62"><gtr:id>08a67913704857049cd961e429f8dd62</gtr:id><gtr:otherNames>Walls GV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1055-8586</gtr:issn><gtr:outcomeId>545a8b3ddfb1d8.98560941</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22DB8DAB-7B7E-4830-8163-A964287EDB39</gtr:id><gtr:title>The long lifespan and low turnover of human islet beta cells estimated by mathematical modelling of lipofuscin accumulation.</gtr:title><gtr:parentPublicationTitle>Diabetologia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/79bb8be53b3f8bb3c002c44b1b79d5e6"><gtr:id>79bb8be53b3f8bb3c002c44b1b79d5e6</gtr:id><gtr:otherNames>Cnop M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0012-186X</gtr:issn><gtr:outcomeId>rBAzm8The88</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>42FBB241-7121-4EBE-A58D-60458D48C34E</gtr:id><gtr:title>MEN1 gene replacement therapy reduces proliferation rates in a mouse model of pituitary adenomas.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08a67913704857049cd961e429f8dd62"><gtr:id>08a67913704857049cd961e429f8dd62</gtr:id><gtr:otherNames>Walls GV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>pm_12939_29_22915754</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>38AEDCBB-F489-4A37-8F76-749D225B472F</gtr:id><gtr:title>The Calcilytic Agent NPS 2143 Rectifies Hypocalcemia in a Mouse Model With an Activating Calcium-Sensing Receptor (CaSR) Mutation: Relevance to Autosomal Dominant Hypocalcemia Type 1 (ADH1).</gtr:title><gtr:parentPublicationTitle>Endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2fb3e361f4680064c89a62f1e0816aa4"><gtr:id>2fb3e361f4680064c89a62f1e0816aa4</gtr:id><gtr:otherNames>Hannan FM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0013-7227</gtr:issn><gtr:outcomeId>56d8b74f479a22.49134190</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0501780</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>